Dermata Therapeutics, Inc. (DRMA) Ownership
DRMA ownership summary
as of October 18, 2026- Institutions
- 7.9% of shares outstanding
- Insiders
- 27.35% of shares outstanding
- Shares outstanding
- 5.0M
- Float
- 2.9M shares available to trade
- Short interest
- 2.07% 84K shares short
- Days to cover
- 2.61 short interest down 29.6% vs prior month
- Institutions 7.91%
- Insiders 27.35%
- Other investors 64.74%
DRMA top institutional holders
17 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.41% | 20K | $17,375 | −28,131 (−58.2%) | June 30, 2026 |
| 2 | Welch & Forbes LLC | 0.40% | 20K | $17,200 | — | June 30, 2026 |
| 3 | State Street Corp | 0.38% | 19K | $16,122 | +18,747 (0.0%) | June 30, 2026 |
| 4 | UBS Group AG | 0.34% | 17K | $14,445 | −18,812 (−52.8%) | June 30, 2026 |
| 5 | Susquehanna International Group, LLP | 0.32% | 16K | $13,751 | +15,989 (0.0%) | June 30, 2026 |
| 6 | XTX Topco Ltd | 0.30% | 15K | $12,717 | +14,787 (0.0%) | June 30, 2026 |
| 7 | Advisory Alpha, LLC | 0.20% | 10K | $8,600 | +10,000 (0.0%) | June 30, 2026 |
| 8 | Tower Research Capital LLC | 0.08% | 3,860 | $3,320 | +3,144 (+439.1%) | June 30, 2026 |
| 9 | Mcf Advisors, LLC | 0.04% | 1,732 | $1,490 | — | June 30, 2026 |
| 10 | Barclays PLC | 0.01% | 270 | $232 | +270 (0.0%) | June 30, 2026 |
| 11 | SBI Securities Co Ltd | <0.01% | 101 | $87 | — | June 30, 2026 |
| 12 | HIGHLINE WEALTH PARTNERS LLC | <0.01% | 26 | $22 | +26 (0.0%) | June 30, 2026 |
| 13 | Morgan Stanley - Brokerage Accounts | 0.00% | 2 | $2 | +2 (0.0%) | June 30, 2026 |
| 14 | Citigroup Inc | 0.00% | — | — | −1 (−100.0%) | June 30, 2026 |
| 15 | JPMorgan Chase & Co | 0.00% | — | — | −696 (−100.0%) | March 31, 2026 |
| 16 | Clear Street Group Inc | 0.00% | — | — | −17,000 (−100.0%) | March 31, 2026 |
| 17 | Bank of America Corp | 0.00% | — | — | −3,457 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 17, 8 holders added 63K shares and 6 cut 68K.
DRMA top mutual fund and ETF holders
2 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.38% | 19K | $16,336 | −102 (−0.5%) | August 31, 2026 |
| 2 | Fidelity Series Total Market Index | 0.02% | 1,106 | $951 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
DRMA insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-17 | Munera Maria E Bedoya-Toro | Buy | $1.27 | 1,000 | $1,270 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
DRMA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns DRMA
Institutional investors own 7.9% of Dermata Therapeutics's shares and insiders 27.35%. The largest holder is Geode Capital Management, LLC with 0.41% of the shares (20K), as of June 30, 2026. Among the top 17 institutions, 8 added shares and 6 reduced their stake in the latest filings. Short interest is 2.07% of the float, or 2.61 days of average trading volume. The share count rose 46.9% since 2020.
Related: DRMA analyst forecast, DRMA key metrics. See the DRMA stock overview for the latest quote and news.
DRMA ownership FAQ
Who owns the most Dermata Therapeutics stock?
The largest shareholders of Dermata Therapeutics are Geode Capital Management, LLC (0.41%), Welch & Forbes LLC (0.40%), State Street Corp (0.38%), UBS Group AG (0.34%), Susquehanna International Group, LLP (0.32%).
What percentage of Dermata Therapeutics is owned by institutions?
Institutions hold 7.9% of Dermata Therapeutics's shares outstanding; insiders hold 27.35%.
Which funds own Dermata Therapeutics?
The largest fund holders of Dermata Therapeutics are Fidelity Extended Market Index (0.38%), Fidelity Series Total Market Index (0.02%).
What is Dermata Therapeutics's short interest?
84K shares of Dermata Therapeutics were sold short, 2.07% of the float; at the average daily volume it would take 2.61 days to cover.
Are insiders buying or selling Dermata Therapeutics?
Of the latest 1 reported insider transactions in Dermata Therapeutics (since February 17, 2026), 1 were purchases and 0 were sales.
How many shares of Dermata Therapeutics are outstanding?
Dermata Therapeutics has 5.0M shares outstanding, of which 2.9M are in the public float.